|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for SCN8A(NM_014191.4) Search again
Product ID:
HQP160586
(click here to view gene annotation page)
Species:
Human
Symbol:
Alias:
BFIS5, CERIII, CIAT, DEE13, EIEE13, MED, MYOCL2, NaCh6, Nav1.6, PN4
Gene Description:
sodium voltage-gated channel alpha subunit 8
Target Gene Accession:
NM_014191.4(click here to view gene page)
Estimated Delivery:
Approximately 1-3 weeks, but may vary. Please email sales@genecopoeia.com or call 301-762-0888 to confirm ETA.
Important Note:
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Summary
Voltage-dependent sodium channels, such as SCN8A, are responsible for the initial membrane depolarization that occurs during generation of action potentials in most electrically excitable cells (Plummer et al., 1998 [PubMed 9828131]).[supplied by OMIM].
Gene References into function
- Beta-scorpion toxin enhance channel activation, which could make it a model drug to replace deep brain stimulation of the subthalamic nucleus in patients with Parkinson disease.
- Mmbrane-binding domain of ankyrin-G is critical for reducing the persistent sodium current of Nav1.6.
- Different mechanisms underlie axonal degeneration in acute and chronic multiple sclerosis, with axonal injury at sites of coexpression of Nav1.6 and sodium-calcium exchanger in acute lesions but independent of coexpression in chronic lesions.
- results demonstrate that genetic interactions can alter seizure severity and support the hypothesis that genetic modifiers contribute to the clinical variability observed in severe myoclonic epilepsy of infancy
